GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Inovio Pharmaceuticals
Inovio is a biotech company pioneering DNA vaccines. Its stock price is a long history of high hopes and disappointments. The chart reflects numerous clinical trials, but so far, no major commercial success.
Share prices of companies in the market segment - Pharma virus
Inovio Pharmaceuticals is a biotechnology company developing DNA vaccines and immunotherapeutic drugs for the treatment of infectious diseases and cancer. We classify it as a "Viral Pharmaceuticals" company. The chart below shows the overall dynamics of this cutting-edge, yet risky, sector.
Broad Market Index - GURU.Markets
Inovio Pharmaceuticals is a biotech company developing DNA vaccines and immunotherapeutic drugs for the treatment of infectious diseases and cancer. Its innovative platform makes it part of the GURU.Markets index. The chart below compares its performance to the market.
Change in the price of a company, segment, and market as a whole per day
INO - Daily change in the company's share price Inovio Pharmaceuticals
For Inovio Pharmaceuticals, the daily price change is a measure of the extreme volatility typical of the biotech sector. This metric reflects reactions to news about clinical trials of its innovative vaccines and is critical to the risk assessment formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma virus
Inovio Pharmaceuticals, Inc. is a biotech company. This chart demonstrates the sector's extreme volatility. Comparison with INO's performance, which focuses on DNA vaccines, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Inovio Pharmaceuticals is a biotech company known for its DNA vaccine platform. The company's shares are extremely sensitive to news about clinical trials and pandemics. This event-driven volatility is a clear example of how biotech influences the entire market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Inovio Pharmaceuticals
For Inovio Pharmaceuticals, year-over-year performance is a story of seeking recognition for its DNA medicine platform. Following the COVID-19 vaccine failure, its 12-month market cap change depends entirely on progress in clinical trials of its drugs for HPV-associated diseases, which is a key opportunity to prove its potential.
Annual dynamics of market capitalization of the market segment - Pharma virus
Inovio Pharmaceuticals, Inc. is a biotechnology company specializing in the development of DNA vaccines and immunotherapies. Its stock price is highly volatile and dependent on clinical trial results. The chart reflects the high risks and potential of its innovative, yet unproven, platform.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Inovio, like other biotechs, is going through a difficult period following the pandemic. Its stock price reflects not economic cycles, but its struggle to find new products and regain investor confidence. This chart tells the story of how the company is adapting to life after its COVID-19 vaccine failed to live up to expectations.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Inovio Pharmaceuticals
Inovio Pharmaceuticals is a biotech company known for its DNA vaccine platform. Its history is full of sharp ups and downs. The monthly fluctuations on the chart chronicle its clinical trials and interactions with the FDA. Funding news and trial data are the main drivers of its extreme volatility.
Monthly dynamics of market capitalization of the market segment - Pharma virus
Inovio Pharmaceuticals is a biotech company specializing in the development of DNA vaccines and immunotherapeutic drugs for the treatment of infectious diseases and cancer. The chart below illustrates the overall dynamics of the biotech sector, where innovative platforms like Inovio's offer both great potential and high risks.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Inovio Pharmaceuticals is a biotech company specializing in the development of DNA vaccines. Its shares are extremely volatile and react to news about clinical trials, partnerships, and government funding. The company's dynamics are completely detached from general market trends, living in the world of medical innovation.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Inovio Pharmaceuticals
The weekly performance of Inovio, a biotech company developing DNA vaccines, is a story of high expectations and disappointments. The stock is highly volatile, reacting to clinical trial data and the company's ability to bring its innovative technology to commercial success.
Weekly dynamics of market capitalization of the market segment - Pharma virus
Inovio Pharmaceuticals develops DNA vaccines and immunotherapeutics. The biotech sector, particularly vaccine-related, is highly sensitive to clinical trial news. This chart helps differentiate investor reactions to Inovio's own data from the broader sentiment that impacts the industry as a whole.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Inovio Pharmaceuticals is a biopharmaceutical company. Its success depends on the results of clinical trials. This chart will help you understand: does Inovio live in its own world of scientific news, or are the overall market conditions and risk appetite in the biotech sector actually influencing its stock price?
Market capitalization of the company, segment and market as a whole
INO - Market capitalization of the company Inovio Pharmaceuticals
Inovio's market capitalization is a dramatic story about a biotech company that has been developing its DNA vaccine platform for decades but has yet to bring a single product to market. Its chart is a series of sharp rises fueled by hopes (including COVID-19) and long declines fueled by disappointments. Its dynamics are a narrative of investor faith and the eternal anticipation of a breakthrough.
INO - Share of the company's market capitalization Inovio Pharmaceuticals within the market segment - Pharma virus
Inovio Pharmaceuticals is a biotech company pioneering the development of DNA drugs and vaccines. Its market capitalization reflects both the significant potential of its platform and the challenges of bringing products to market. This chart shows how the market views its years-long efforts to develop a new class of drugs.
Market capitalization of the market segment - Pharma virus
Inovio is a biotech company known for its DNA vaccine platform. The chart below shows the overall market capitalization of this sector. Its extreme volatility tells the story of high hopes during the pandemic and the subsequent difficulties in bringing innovative technology to market.
Market capitalization of all companies included in a broad market index - GURU.Markets
Inovio is a biotech company developing DNA vaccines and drugs. Its market capitalization is a bet on its unique technological platform. Its volatile performance on the overall chart tells the story of the long journey from scientific concept to approved product, full of hopes and disappointments.
Book value capitalization of the company, segment and market as a whole
INO - Book value capitalization of the company Inovio Pharmaceuticals
Inovio's book value is derived from its equity and patents for its unique DNA vaccine technology. This is the tangible, scientific foundation for creating a new generation of vaccines against infectious diseases and cancer. How has this innovative, yet highly tested, asset evolved? The chart below tells its dramatic story.
INO - Share of the company's book capitalization Inovio Pharmaceuticals within the market segment - Pharma virus
Inovio Pharmaceuticals develops DNA vaccines and immunotherapies, which require laboratories and specialized equipment for drug delivery. The chart shows the share of these unique tangible assets, reflecting the physical foundation of its innovative platform.
Market segment balance sheet capitalization - Pharma virus
Inovio Pharmaceuticals develops DNA vaccines. Its main value lies in its technological platform, not its production capacity. The book value chart will show how "light" the company's material base is at the forefront of biotechnology.
Book value of all companies included in the broad market index - GURU.Markets
Inovio Pharmaceuticals is a pioneer in DNA medicine. Its book value is determined by its DNA plasmid production facilities, laboratories, and patent portfolio. The chart shows the material foundation upon which innovative vaccines and next-generation drugs are built.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Inovio Pharmaceuticals
Inovio's balance sheet is made up of capital and patents. Its market value is the belief in its DNA vaccine platform. The chart shows how this belief has skyrocketed during the pandemic and then plummeted due to research setbacks. It's one of the most volatile "hope ratios."
Market to book capitalization ratio in a market segment - Pharma virus
Inovio Pharmaceuticals is a biotech company developing DNA vaccines and immunotherapies. Its value is based on the potential of its unique technology platform. The chart shows investor expectations for its ability to develop new drugs.
Market to book capitalization ratio for the market as a whole
Inovio Pharmaceuticals is a biotech company developing DNA vaccines and immunotherapeutics. Its technology enables the delivery of DNA plasmids directly into cells. This chart shows the overall market valuation, but how do investors value a company with an innovative but unproven technology platform?
Debts of the company, segment and market as a whole
INO - Company debts Inovio Pharmaceuticals
Inovio Pharmaceuticals, a biotech company with a DNA vaccine platform, has raised significant capital. This chart tells the story of its funding for its extensive pipeline, including a much-discussed but ultimately unmarketed COVID-19 vaccine, reflecting the high risks in this industry.
Market segment debts - Pharma virus
Inovio Pharmaceuticals is developing DNA vaccines and immunotherapies. This technology has great potential, but bringing it to market has proven challenging. This chart shows how the company continues to fund its research and development after years of work without a commercial product.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Inovio Pharmaceuticals
Inovio Pharmaceuticals is a biotech company known for its DNA vaccine development platform. This chart shows how dependent it is on debt to finance its numerous clinical programs. For a company with an innovative technology that has yet to produce a commercial product, debt management is a matter of survival.
Market segment debt to market segment book capitalization - Pharma virus
Inovio Pharmaceuticals is a biotech company developing DNA vaccines and immunotherapeutic drugs against infectious diseases and cancer. This chart shows the overall debt burden in the biotech sector. It helps understand how companies finance their innovative platforms and expensive clinical trials.
Debt to book value of all companies in the market
Inovio Pharmaceuticals is a biotech company working on DNA vaccines. After years of development, it is still in clinical trials. The market's total debt burden chart doesn't reflect its reality: the company relies on shareholders' funds, and its main risk isn't debt, but rather obtaining regulatory approval for its products.
P/E of the company, segment and market as a whole
P/E - Inovio Pharmaceuticals
For Inovio Pharmaceuticals, a company developing DNA vaccines and drugs, this chart shows how investor expectations have shifted. After heightened attention during the pandemic, the multiple now reflects a more sober view of the challenges of bringing its innovative, yet unproven, technology platform to market.
P/E of the market segment - Pharma virus
Developing DNA vaccines, where Inovio was a pioneer, is a high-risk business. This chart shows the average valuation for biopharmaceutical companies. It helps to understand that Inovio, after the failure of its COVID-19 vaccine, is being valued based on the potential of its platform for treating other diseases, but with considerable skepticism from investors.
P/E of the market as a whole
Inovio Pharmaceuticals is a biotech company developing DNA vaccines and immunotherapies for the treatment of infectious diseases and cancer. The company has attracted significant attention during the pandemic. This biotech sentiment chart helps understand how the market views the potential of Inovio's unique, yet uncommercialized, platform.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Inovio Pharmaceuticals
Inovio Pharmaceuticals is a biotech company developing DNA vaccines and immunotherapeutics. This chart reflects investor expectations for its technology platform after past mixed results. The trend represents the market's assessment of the likelihood of success for its current clinical programs.
%20P%2FE%20Inovio%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Inovio-Pharmaceuticals&v=1772691072278 "Chart of the company's future (projected) P/E Inovio Pharmaceuticals")
Future (projected) P/E of the market segment - Pharma virus
Inovio Pharmaceuticals is a biotech company developing DNA vaccines and immunotherapeutics. This chart shows average profitability expectations for the sector. It provides insight into how the market views the company's technology platform following the COVID-19 vaccine setback and the potential of its other developments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-virus&v=1772691072307 "Future (projected) P/E graph of the market segment - Pharma virus")
Future (projected) P/E of the market as a whole
Inovio Pharmaceuticals is a biotech company developing DNA vaccines and immunotherapeutic drugs for the treatment of infectious diseases and cancer. This chart shows investors' risk appetite. For a company with an innovative but not yet fully validated technology platform, it reflects the market's confidence in its long-term potential.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772691072323 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Inovio Pharmaceuticals
Inovio Pharmaceuticals is a biotechnology company developing DNA vaccines and immunotherapeutics. The financial result illustrated by this chart is comprised of expenses on numerous clinical trials. It shows the cost of advancing an innovative technological platform that has the potential to be used against a wide range of diseases.
Profit of companies in the market segment - Pharma virus
Inovio Pharmaceuticals is a biotech company developing DNA vaccines and immunotherapies for the treatment of infectious diseases and cancer. Its technology uses electroporation to deliver plasmids into cells. This graph illustrates the long and risky path to profitability in biotech, where innovative platforms like Inovio's must prove their effectiveness.
Overall market profit
Inovio Pharmaceuticals is a biotechnology company developing DNA vaccines and immunotherapeutics. Its technology is innovative, but has not yet resulted in a commercial product. Like many companies in this field, access to financing, which becomes easier during periods of economic strength, is key to Inovio's survival.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Inovio Pharmaceuticals
Inovio Pharmaceuticals is a biotech company developing DNA vaccines and immunotherapeutics. The earnings forecast in this chart reflects analysts' expectations for the clinical trial results of its platform for treating infectious diseases and cancer.
%20profit%20of%20the%20company%20Inovio%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Inovio-Pharmaceuticals&v=1772691072441 "Graph of future (projected) profit of the company Inovio Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Pharma virus
Inovio Pharmaceuticals is a biotechnology company pioneering the development of DNA vaccines and immunotherapeutics for the treatment of infectious diseases and cancer. This chart shows the revenue forecast for the viral pharmaceuticals sector, providing insight into how the market perceives the potential of Inovio's innovative, yet unproven, platform.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-virus&v=1772691072468 "Graph of future (predicted) profits of companies in a market segment - Pharma virus")
Future (predicted) profit of the market as a whole
Inovio Pharmaceuticals is a biotech company developing DNA vaccines. Its success depends on clinical trial results and regulatory approval. This schedule, reflecting market sentiment, affects the availability of funding needed to conduct expensive research and bring the drugs to market.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772691072476 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Inovio Pharmaceuticals
Inovio Pharmaceuticals is a biotech company developing DNA vaccines and immunotherapeutics. This chart shows how investors value its revenue, which is dependent on clinical trial success. This valuation reflects confidence in its unique technology platform, despite past setbacks.
P/S market segment - Pharma virus
Inovio Pharmaceuticals is a biotech company pioneering the development of DNA vaccines and immunotherapies for the treatment of infectious diseases and cancer. This chart shows the industry average market capitalization to revenue ratio, reflecting how investors view the potential of the company's unique drug delivery platform.
P/S of the market as a whole
Inovio Pharmaceuticals is a biotech company developing DNA vaccines and immunotherapeutics for the treatment of infectious diseases and cancer. The company is a pioneer in this technology. This chart helps understand how the market values innovative, but not yet fully commercially proven, biotech platforms.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Inovio Pharmaceuticals
Inovio Pharmaceuticals is a biotech company developing DNA vaccines and immunotherapeutics. This chart shows its valuation relative to future projected sales. It reflects investor expectations for the success of its technology platform and the approval of its products in development.
%20P%2FS%20Inovio%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Inovio-Pharmaceuticals&v=1772691072540 "The graph of the company's future (projected) P/S Inovio Pharmaceuticals")
Future (projected) P/S of the market segment - Pharma virus
Inovio Pharmaceuticals is a biotech company developing DNA vaccines and immunotherapeutics for the treatment of infectious diseases and cancer. Its drug delivery technology is key. This chart reflects investor expectations for its innovative platform and future revenue, which is contingent on the approval of its products.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20virus&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-virus&v=1772691072547 "Future (projected) P/S market segment graph - Pharma virus")
Future (projected) P/S of the market as a whole
Inovio Pharmaceuticals is a biotech company developing DNA vaccines and immunotherapies. Its future depends on the success of its clinical programs and regulatory approvals. This chart of overall expectations for INO is merely a backdrop. The company's value is determined by scientific breakthroughs and investor confidence in its technological platform, not by the overall state of the economy.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772691072570 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Inovio Pharmaceuticals
This chart illustrates the complex journey of a biotech company. For Inovio Pharmaceuticals, which develops DNA vaccines and immunotherapies, it reflects grants and partnerships to fund its numerous clinical trials, rather than consistent sales revenue.
Sales of companies in the market segment - Pharma virus
Inovio Pharmaceuticals develops DNA vaccines and immunotherapeutic drugs against infectious diseases and cancer. Its delivery technology is a key innovation. This chart shows revenue in the pharmaceutical sector. The success of Inovio's platform could lead to the creation of a new generation of vaccines and significantly impact the future growth of the industry.
Overall market sales
Inovio Pharmaceuticals is a biotechnology company developing DNA vaccines and immunotherapeutics. Its innovative platform has the potential to accelerate the development of vaccines against infectious diseases and cancer. The company's success depends on clinical trials and exemplifies how cutting-edge science is shaping the future of healthcare.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Inovio Pharmaceuticals
Inovio Pharmaceuticals develops DNA vaccines and immunotherapeutic drugs for the treatment of infectious diseases and cancer. Future sales projections depend on regulatory approval of its innovative platform, which has not yet launched a single product.
%20sales%20of%20the%20company%20Inovio%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Inovio-Pharmaceuticals&v=1772691072629 "Schedule of future (projected) sales of the company Inovio Pharmaceuticals")
Future (projected) sales of companies in the market segment - Pharma virus
Inovio Pharmaceuticals develops DNA vaccines and immunotherapeutics. The forecast for the antiviral pharmaceutical and immunology sector demonstrates the demand for new platforms. The graph reflects how the pandemic has spurred interest in innovative vaccine technologies that can be quickly adapted to new threats.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-virus&v=1772691072671 "Schedule of future (projected) sales of companies in the market segment - Pharma virus")
Future (projected) sales of the market as a whole
Inovio Pharmaceuticals is a biotechnology company developing DNA vaccines and immunotherapeutics. Its prospects depend on the success of clinical trials and regulatory approval. This overall economic activity graph does not affect demand for its products, but it is important for assessing the overall investment climate, which influences the financing of biotech companies.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772691072752 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Inovio Pharmaceuticals
Inovio Pharmaceuticals is a biotech company developing DNA vaccines and immunotherapies for the treatment of infectious diseases and cancer. Its financial picture is determined by the enormous expenditures on clinical trials. This chart illustrates the cost of developing and marketing its innovative technology platform, not its current profits.
Market segment marginality - Pharma virus
Inovio Pharmaceuticals is a biotechnology company developing DNA vaccines and immunotherapeutics. Profitability depends on the success of its platform and regulatory approvals for its products. This metric reflects the company's investment in innovative technology compared to traditional vaccine manufacturers.
Market marginality as a whole
Inovio Pharmaceuticals, Inc. is a biotechnology company developing DNA vaccines and immunotherapies. This chart reflects average revenue. Compared to this, Inovio is a story of a long and, so far, unsuccessful pursuit of a commercial product. Despite its promising technology, the company has not yet brought a single drug to market, which is reflected in its financial performance.
Employees in the company, segment and market as a whole
Number of employees in the company Inovio Pharmaceuticals
Inovio Pharmaceuticals is a biotechnology company developing DNA vaccines and immunotherapeutics. Its workforce dynamics in this chart reflect its research activities. Growth is driven by the launch of new clinical trials, while layoffs may follow restructuring or a change in priorities within its development portfolio.
Share of the company's employees Inovio Pharmaceuticals within the market segment - Pharma virus
Inovio Pharmaceuticals is a biotechnology company pioneering the development of DNA vaccines and immunotherapeutics delivered via a proprietary electroporation device. This chart illustrates its unique technology platform, reflecting the proportion of scientists and engineers working at the intersection of genetic engineering and medical technology within Inovio.
Number of employees in the market segment - Pharma virus
Inovio Pharmaceuticals is a biotechnology company developing DNA vaccines and immunotherapeutics. This chart illustrates the long journey of innovative technologies to market. The dynamics of scientists and clinicians' workload reflects the progress and setbacks of the multi-year clinical trials required to prove the effectiveness of a new platform.
Number of employees in the market as a whole
Inovio Pharmaceuticals is a biotech company developing DNA vaccines. Their stock often reacts to news about infectious disease outbreaks. The overall economic situation, as shown by this chart, is secondary to their performance. The main drivers are progress in clinical trials and funding from government and non-profit organizations.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Inovio Pharmaceuticals (INO)
Inovio Pharmaceuticals is a biotech company developing DNA vaccines and immunotherapies for the treatment of infectious diseases and cancer. This chart shows how the market values these innovative platforms. Their high market capitalization per employee reflects the potential of their unique technology, which could enable the rapid development of new vaccines against emerging threats.
%20of%20the%20company%20Inovio%20Pharmaceuticals%20(INO)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Inovio-Pharmaceuticals-INO&v=1772691072907 "Chart of market capitalization per employee (in thousands of dollars) of the company Inovio Pharmaceuticals (INO)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma virus
Inovio Pharmaceuticals develops DNA vaccines and immunotherapeutics. It is a cutting-edge biotech platform. This chart clearly demonstrates how the market views the potential of this technology. The high cost per employee indicates that investors believe a small team of scientists is capable of creating a whole line of breakthrough products.
%20by%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-virus&v=1772691072908 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma virus")
Market capitalization per employee (in thousands of dollars) for the overall market
Inovio Pharmaceuticals is a biotechnology company developing DNA vaccines and immunotherapeutics. This chart shows how the market values a company with an innovative, but not yet fully commercially proven, technology platform.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772691072923 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Inovio Pharmaceuticals (INO)
Inovio Pharmaceuticals is a biotech company developing DNA vaccines and drugs delivered via their proprietary device (CELLECTRA). They are working on vaccines for COVID-19, Ebola, and cancer treatments. This is an R&D platform. This metric is negative. It shows how much the company spends on each scientist to advance its unique DNA technology.
%20Chart%20Inovio%20Pharmaceuticals%20(INO)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Inovio-Pharmaceuticals-INO&v=1772691072986 "Company Profit Per Employee (in thousands of dollars) Chart Inovio Pharmaceuticals (INO)")
Profit per employee (in thousands of dollars) in the market segment - Pharma virus
Inovio Pharmaceuticals (INO) is a biotech company known for its DNA vaccine platform. Like many R&D companies, this chart shows a future goal. After years of research, INO's profitability still depends on the success of its clinical trials. If approved, their platform could generate very high profits per employee.
%20in%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-virus&v=1772691072998 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma virus")
Profit per employee (in thousands of dollars) for the market as a whole
Inovio Pharmaceuticals (INO) is a biotech company known for its DNA vaccines. The company has been in R&D for decades. This chart, showing negative profit per employee, illustrates the enormous, multi-year investment in its research team in anticipation of approval for at least one drug in its broad pipeline.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772691073040 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Inovio Pharmaceuticals (INO)
Inovio Pharmaceuticals is a biotech company developing DNA vaccines and immunotherapies. This chart reflects its status as a clinical-stage R&D company. Lack of revenue is normal. This metric demonstrates potential: a successful product can generate significant revenue with a small staff.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Inovio-Pharmaceuticals-INO&v=1772691073080 "Sales chart per company employee Inovio Pharmaceuticals (INO)")
Sales per employee in the market segment - Pharma virus
Inovio Pharmaceuticals is a biotech company specializing in the development of DNA vaccines and immunotherapies (delivered via their proprietary CELLECTRA device). During the R&D phase, this metric reflects how effectively their scientific team generates revenue (through partnerships or grants) by advancing their platform.
Sales per employee for the market as a whole
Inovio Pharmaceuticals is a biotech company specializing in the development of DNA vaccines and immunotherapies. They were widely known during the pandemic. This chart shows revenue per employee. It is likely close to zero and consists of grants or partnership payments, as the company still has no approved commercial products.
Short shares by company, segment and market as a whole
Shares shorted by company Inovio Pharmaceuticals (INO)
Inovio Pharmaceuticals is a biotech company known for its DNA vaccines and delivery devices (Cellectra). The company has been promising breakthroughs for years, but has no approved products. This chart shows bearish bets. Bears are betting that DNA vaccine technology is ineffective and that the company will continue to burn through capital without results.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Inovio-Pharmaceuticals-INO&v=1772691073149 "Short Shares Chart for the Company Inovio Pharmaceuticals (INO)")
Shares shorted by market segment - Pharma virus
Inovio Pharmaceuticals is a biotech company developing DNA vaccines and immunotherapies. This chart shows overall short positions in the biotech sector. A high value reflects general market skepticism about the sector, possibly due to fears of research failures or tightening regulatory policies (e.g., the FDA) across the sector.
Shares shorted by the overall market
Inovio (INO) is a biotech company whose reputation is built on "stories" and R&D. When this market fear indicator rises, investors run out of patience. They sell off unprofitable "research projects" like INO en masse, preferring companies with real profits.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Inovio Pharmaceuticals (INO)
Inovio Pharmaceuticals is a biotech company with a long history of development (DNA vaccines), but no approved products. The stock is highly speculative. A chart above 70 may reflect rare positive R&D news. A range below 30 is often associated with setbacks, delays, or a loss of investor confidence.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Inovio-Pharmaceuticals-INO&v=1772691073170 "RSI 14 indicator chart for the company's stock Inovio Pharmaceuticals (INO)")
RSI 14 Market Segment - Pharma virus
Inovio (INO) is a "biotech" (DNA vaccines), the star of the COVID hype. Their specialty is delivering DNA vaccines via an electronic device (CELLECTRA). The "Pharma virus" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand: is INO's growth due to their R&D, or is the entire biotech sector "overheated"?
RSI 14 for the overall market
For Inovio, a biotech company in the R&D stage, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast INO (Inovio Pharmaceuticals)
Inovio Pharmaceuticals is a biotech company developing DNA vaccines and immunotherapies for the treatment of infectious diseases and cancer. This chart shows the average analyst forecast. Their targets are based on an assessment of the clinical data of its platform and the company's ability to bring at least one product to market.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-INO-Inovio-Pharmaceuticals&v=1772691073238 "A chart showing analyst consensus forecasts for the expected stock price. INO (Inovio Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price INO (Inovio Pharmaceuticals)
Inovio is a biotech company pioneering DNA vaccines and immunotherapies for the treatment of viruses and cancer. This chart shows how far the current share price differs from the "fair" value predicted by analysts. It reflects their belief (or skepticism) that their DNA platform will finally achieve commercial success.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-INO-Inovio-Pharmaceuticals&v=1772691073243 "A chart showing the difference between the consensus forecast and the actual stock price. INO (Inovio Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Pharma virus
Inovio is a biotech company that has been trying for decades to prove the viability of its DNA vaccine platform (delivered via electric shock). This chart reflects analyst expectations across the pharmaceutical sector, demonstrating whether experts believe this risky R&D platform will succeed.
Analysts' consensus forecast for the overall market share price
Inovio (INO) is a biotech company working on "DNA medicine." They are developing a platform for creating vaccines and drugs for viruses (COVID, MERS) and cancer. This chart shows the overall risk appetite. It reflects the willingness of investors to continue funding R&D platforms that have not yet brought a product to market.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Inovio Pharmaceuticals
Inovio is a biotech veteran that has been promising revolution for decades, but has yet to launch a single product. Their specialty is DNA vaccines, delivered via their specialized electrical device (Cellectra). This chart is a summary indicator of both faith and disappointment. It reflects their (failed) attempts to create a COVID vaccine and their ongoing R&D in oncology and virology.
AKIMA Market Segment Index - Pharma virus
Inovio Pharmaceuticals is a biotech company known for its DNA vaccine platform, which is delivered via a specialized device (Cellectra). This chart shows the average index for the antiviral drug sector. It helps investors assess how Inovio's performance, with its unique technology, compares to the industry average.
The AKIM Index for the overall market
Inovio Pharmaceuticals is a biotech company developing DNA drugs and vaccines (HPV, cancer). It is known for its electroporation delivery platform. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this company, which is striving to prove the effectiveness of its technology, compares to overall economic trends.
